IFNB1 and myeloid sarcoma: Interferon–β (IFN–β) is a first-line treatment for relapsing-remitting (RR)MS [11], [12] shown to exert potent immunoregulatory effects on myeloid cells such as monocytes, [13] and likely to confer neuroprotection through secretion of neuroprotective factors, [14] including HGF by microglia.